Abstract
Background: Leishmaniasis is a neglected disease that affects 15 million people around the world. Many limitations are associated to the treatment as high cost and toxicity. Several classes of natural substances with proven leishmanicidal activity were reported in the literature. Phytochemsitry study of Anaxagorea dolichocarpa (Annonacea) reported the isolation of aporphine alkaloids.
Methods: In this study, we evaluate the potential activity of the azaphenanthrene alkaloids eupolaramine, imbiline 1, imbiline 4, sampangine, 3-metoxisampangine and 4- metoxisampangine, isolated from A. dolichocarpa, together with a homemade databank of 142 aporphynic alkaloids isolated from Annonaceae, through ligand-based and structurebased virtual screening (VS) against Leishmania donovani. A diverse set selected from CHEMBL databank of 1397 structures, with tested antileishmanial activity against promastigote L. donovani, were classified according pIC50 values in order to generate and validate Random Forest model that show higher statistical indices values. The structure of six different L. donovani enzymes were downloaded from PDB databank and alkaloids structures were submitted to molecular docking.
Results: From the six azaphenanthrene alkaloids, sampangine, 3-methoxy, and 4-methoxy were indicated as potential actives by the RF model. Docking results gave similar values for all six azaphenanthrene alkaloids. So, we performed in vitro tests with sampangine, imbiline 1, imbiline 4, and eupolaramine, which are available in our laboratory, and that show significant values of pIC50 (> 5.26).
Conclusion: Combined approach of VS allowed us to select that aporphynic alkaloid xyloguyelline as potential multitarget compound for leishmanial treatment, presenting activity against five strategic enzymes to treatment with probability of activity over 60% by RF model.
Keywords: Alkaloids, Anaxagorea dolichocarpa, Virtual Screening, Molecular Docking, Random Forest, Leishmania donovani, antileishmania activity.
Current Pharmaceutical Design
Title:Structure- and Ligand-Based Approaches to Evaluate Aporphynic Alkaloids from Annonaceae as Multi-Target Agent Against Leishmania donovani
Volume: 22 Issue: 34
Author(s): Vitor Prates Lorenzo, Ana Silvia Suassuna Carneiro Lúcio, Luciana Scotti, Josean Fechine Tavares, José Maria Barbosa Filho, Tatjana Keesen de Souza Lima, Juliana da Câmara Rocha and Marcus Tullius Scotti
Affiliation:
Keywords: Alkaloids, Anaxagorea dolichocarpa, Virtual Screening, Molecular Docking, Random Forest, Leishmania donovani, antileishmania activity.
Abstract: Background: Leishmaniasis is a neglected disease that affects 15 million people around the world. Many limitations are associated to the treatment as high cost and toxicity. Several classes of natural substances with proven leishmanicidal activity were reported in the literature. Phytochemsitry study of Anaxagorea dolichocarpa (Annonacea) reported the isolation of aporphine alkaloids.
Methods: In this study, we evaluate the potential activity of the azaphenanthrene alkaloids eupolaramine, imbiline 1, imbiline 4, sampangine, 3-metoxisampangine and 4- metoxisampangine, isolated from A. dolichocarpa, together with a homemade databank of 142 aporphynic alkaloids isolated from Annonaceae, through ligand-based and structurebased virtual screening (VS) against Leishmania donovani. A diverse set selected from CHEMBL databank of 1397 structures, with tested antileishmanial activity against promastigote L. donovani, were classified according pIC50 values in order to generate and validate Random Forest model that show higher statistical indices values. The structure of six different L. donovani enzymes were downloaded from PDB databank and alkaloids structures were submitted to molecular docking.
Results: From the six azaphenanthrene alkaloids, sampangine, 3-methoxy, and 4-methoxy were indicated as potential actives by the RF model. Docking results gave similar values for all six azaphenanthrene alkaloids. So, we performed in vitro tests with sampangine, imbiline 1, imbiline 4, and eupolaramine, which are available in our laboratory, and that show significant values of pIC50 (> 5.26).
Conclusion: Combined approach of VS allowed us to select that aporphynic alkaloid xyloguyelline as potential multitarget compound for leishmanial treatment, presenting activity against five strategic enzymes to treatment with probability of activity over 60% by RF model.
Export Options
About this article
Cite this article as:
Lorenzo Prates Vitor, Lúcio Silvia Suassuna Carneiro Ana, Scotti Luciana, Tavares Fechine Josean, Filho Maria Barbosa José, Lima Keesen de Souza Tatjana, Rocha da Câmara Juliana and Scotti Tullius Marcus, Structure- and Ligand-Based Approaches to Evaluate Aporphynic Alkaloids from Annonaceae as Multi-Target Agent Against Leishmania donovani, Current Pharmaceutical Design 2016; 22 (34) . https://dx.doi.org/10.2174/1381612822666160513144853
DOI https://dx.doi.org/10.2174/1381612822666160513144853 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-HER2 Treatment and Breast Cancer: State of the Art, Recent Patents, and New Strategies
Recent Patents on Anti-Cancer Drug Discovery Impact of PLK-1 Silencing on Endothelial Cells and Cancer Cells of Diverse Histological Origin
Current Gene Therapy Transductional Targeting of Adenoviral Cancer Gene Therapy
Current Gene Therapy Evaluation of <sup>177</sup>Lu-EDTMP in Dogs with Spontaneous Tumor Involving Bone: Pharmacokinetics, Dosimetry and Therapeutic Efficacy
Current Radiopharmaceuticals Mucoadhesive Chitosan Derivatives as Novel Drug Carriers
Current Pharmaceutical Design Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions
Current Drug Targets Chronic Hepatitis C and Alcohol Abuse: The Single Center Experience of Novi Sad - Serbia
Reviews on Recent Clinical Trials Pharmacological Modulation of Microparticle Release: New Strategies for the Management of Atherothrombotic Vascular Disorders
Current Pharmaceutical Design Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry Mitochondrial Proteases as Emerging Pharmacological Targets
Current Pharmaceutical Design Evidences of Monomer, Dimer and Trimer of Recombinant Human Cyclophilin A
Protein & Peptide Letters Ca2+ Mediates the Adhesion of Breast Cancer Cells in Self-Assembled Multifunctional Microfluidic Chip Prepared with Carbohydrate Beads
Micro and Nanosystems Editorial
Current Cancer Therapy Reviews Small Molecule Protein-Protein Inhibitors for the p53-MDM2 Interaction
Current Topics in Medicinal Chemistry Evaluation of Tissue and Serum Expression Levels of Lactate Dehydrogenase Isoenzymes in Patients with Head and Neck Squamous Cell Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Insulin-like Growth Factor-1 Receptor (IGF-1R) Kinase Inhibitors in Cancer Therapy: Advances and Perspectives
Current Pharmaceutical Design Reconstructing the Hsp90/Tau Machine
Current Enzyme Inhibition A Potent Inhibitor of Steroid Sulfatase (EM-1913) Blocks Tumor Growth in Nude Mice (MCF-7 Xenograft)
Current Enzyme Inhibition Recent Progress in the Syntheses and Biological Evaluation of Boronated Porphyrins for Boron Neutron-Capture Therapy
Anti-Cancer Agents in Medicinal Chemistry Targeting Plasmodium Falciparum Purine Salvage Enzymes: A Look At Structure-Based Drug Development
Infectious Disorders - Drug Targets